# Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine

> **NCT00435812** · PHASE3 · COMPLETED · sponsor: **Dynavax Technologies Corporation** · enrollment: 2428 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** HEPLISAV and/or Placebo
- **BIOLOGICAL:** Engerix-B

## Key facts

- **NCT ID:** NCT00435812
- **Lead sponsor:** Dynavax Technologies Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-02
- **Final completion:** 2008-03
- **Target enrollment:** 2428 (ACTUAL)
- **Last updated:** 2019-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00435812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00435812, "Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00435812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*